Enbrol Inj (Etanercept 25mg)

Home >> Products >> Injections >> Enbrol Inj

Each 1 ml contains:
Composition:
Etanercept .......................................................................25 mg

Indications:
For reducing signs and symptoms and inhibiting the progress of structural damage in patients with moderately to severely active rheumatoid arthritis. In combination with methotrexate in patients who do not respond to methotrexate alone. To reduce symptoms and signs of moderately to severely active poly-articular-course juvenile rheumatoid arthritis (JRA) in patients who have had an inadequate response to one or more DMARDs.

Description:
Etanercept inhibits TNF activity by competitively binding to it and preventing interactions with its cell surface receptors. Elevated levels of TNF have been found in psoriatic skin lesions, and in synovial explants and fluid from patients with psoriatic arthritis. Furthermore, TNF levels in the serum of patients with plaque psoriasis, and in blister fluids of involved psoriatic skin have also been shown to be higher than in those of controls. These values were significantly correlated with the psoriasis area and severity index (PASI) scores, and TNF levels were reduced in association with clinical resolution after effective treatment.

The production of chemokines, and the expression of adhesion molecules by keratinocytes and vascular endothelial cells can be stimulated by TNF produced within psoriatic lesions. These signals then cause recruitment of additional inflammatory cells into the plaque. Krueger suggests that TNF may function as part of a positive feedback loop, which acts to amplify and sustain the inflammatory process within psoriatic plaques.[10] Biologic responses that are induced or regulated by TNF are modulated by etanercept. It may, therefore, serve to reduce inflammation within plaques by breaking this cycle.

Dosage:
Adults: 25mg given twice weekly as a subcutaneous injection 72-96 hours apart. Methotrexate, glucocorticoids, NSAIDs, or analgesics may be continued during treatment with etanercept. JRA patients: For paediatric patients (4 to 17 years), dose is 0.4mg/kg (up to a maximum of 25mg per dose) given twice weekly as a subcutaneous injection 72-96 hours apart. Glucocorticoids, NSAIDs, or analgesics may be continued during treatment with etanercept.

Presentations: Vial 1 ml